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MT-II, a Lys49PLA2 homologue devoid of catalytic activity from B. asper venom, stimulates in�ammatory events in macrophages.
�e investigated the ability ofMT-II to induce formation of lipid droplets (LDs), key elements of in�ammatory responses, in isolated
macrophages and participation of protein kinases and intracellular PLA2s in this eﬀect. In�uence of MT-II on PLI�2 recruitment
and expression was assessed, and the eﬀects of some synthetic peptides on LD formation were further evaluated. At noncytotoxic
concentrations,MT-II directly activatedmacrophages to formLDs.is eﬀect was reproduced by a synthetic peptide corresponding
to the C-terminal sequence 115–129 of MT-II, evidencing the critical role of C-terminus for MT-II-induced eﬀect. Moreover,
MT-II induced expression and recruitment of PLI�2. Pharmacological interventions with speci�c inhibitors showed that PKC,
PI3K, ERK1/2, and iPLA2, but not P38MAPK or cPLA2, signaling pathways are involved in LD formation induced by MT-II. is
sPLA2 homologue also induced synthesis of PGE2 that colocalized to LDs. In conclusion, MT-II is able to induce formation of LDs
committed to PGE2 formation in a process dependent on C-terminal loop engagement and regulated by distinct protein kinases
and iPLA2. LDs may constitute an important in�ammatory mechanism triggered by MT-II in macrophages.
1. Introduction
Phospholipases A2s (PLA2; EC 3.1.1.4) constitute a family of
lipolytic enzymes with key roles in several cellular processes
by regulating the release of arachidonic acid and lysophos-
pholipids from cell membrane phospholipids. Venoms from
snakes of the Viperidae family contain group IIA phospho-
lipases A2 (PLA2s), which share structural and functional
features with PLA2s found in in�ammatory exudates in
mammals [1, 2]. A number of Bothrops snake venom PLA2s
have been shown to induce in�ammatory events such as
edema and leukocyte in�ltration and to directly activate
in�ammatory cell functions [3–6].
Basic PLA2s are considered the most important venom
components responsible for the severe local myotoxicity and
in�ammation characteristic of the envenomation induced by
Bothrops genus snakes [7].ese enzymes are further divided
into two subgroups, namely, catalytically active variants,
presenting a conserved aspartic acid residue at position
49 (Asp49PLA2s), and catalytically inactive homologues,
known as Lys49PLA2s, which present various substitutions
in residues of the Ca2+ binding loop, as well as at position
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49, where Lys replaces the highly conserved Asp [8, 9]. Such
modi�cations drastically aﬀect the catalytic ability of these
proteins rendering these homologues enzymatically inac-
tive [10]. Interestingly, Lys49PLA2 homologues are highly
myotoxic, bactericidal, and proin�ammatory [9], evidencing
that phospholipid hydrolysis is not strictly required for these
activities. Studies on synthetic peptides and site-directed
mutagenesis identi�ed the C-terminal region of Lys49PLA2s
as essential for their biological activities [10, 11]. us,
Lys49PLA2 homologues constitute interesting models to
investigate a series of cellular eﬀects which do not depend on
membrane phospholipid hydrolysis.
In the Bothrops asper snake venom three myotoxic Lys49-
PLA2s have been identi�ed, namedMT-II,MT-IV, andM1-3-
3, and reported in UNIPROT database. Besides myotoxicity,
MT-II, the most studied Lys49PLA2 homologue, has been
reported to induce in�ammation in vivo [5, 12] and to
activate some in�ammatory functions of macrophages in
vitro, increasing phagocytosis, respiratory burst, and release
in�ammatory mediators [4] at noncytotoxic concentrations.
However, the knowledge on the eﬀects of this Lys49PLA2 in
macrophages functions, is still fragmentary.
Macrophages play key roles in a wide variety of pro-
cesses associated with tissue maintenance, antigen presenta-
tion, in�ammation, and tissue repair [13]. Upon in�amma-
tory stimuli, quiescent macrophages become activated and
present increased number of lipid rich cytoplasmic organelles
named lipid droplets (LDs), also known as lipid bodies.
ese organelles are functionally involved in biosynthesis,
transport, and catabolism of lipids [14, 15] as well as biosyn-
thesis and accumulation of in�ammatory mediators, such
as eicosanoids and cytokines [16, 17]. Moreover, leukocyte
LDs associated with in�ammatory responses have been
shown to compartmentalize signaling proteins involved in
cellular activation and structural proteins, mainly perilipin
2 (PLIN2), also named adipophilin (Adipose diﬀerentiation-
related protein, ADRP), which has an important role in
LD assembly and formation of foam macrophages [18, 19],
which are markers of atherosclerotic plaques [19]. Increased
numbers of lipid droplets are described in distinct popu-
lations of leukocytes during in�ammatory and infectious
processes [20, 21]. Recently, MT-III, a catalytically active
variant Asp49PLA2 from B. asper venom, has been shown
to activate macrophages to form increased amounts of LDs
[22], but no such eﬀect has been described for the action
of Lys49PLA2s. erefore, it is relevant to assess the eﬀects
of MT-II on macrophages in terms of LD formation. Such
macrophage activation might play a relevant role in the
scenario of the local pathological alterations induced by
snake venom toxins. Based on these information, in the
present study the ability of MT-II to induce LD formation
in macrophages was evaluated and the mechanisms involved
in this eﬀect were analyzed in terms of recruitment and
expression of PLIN2, participation of intracellular PLA2s
(cPLA2 and iPLA2) and signaling protein kinases. In light
of the absence of catalytic activity in MT-II, the eﬀects of
some synthetic peptides related to distinct regions of this
Lys49PLA2 molecule on lipid droplet formation were further
evaluated in macrophages.
2. Materials andMethods
2.1. Chemicals and Reagents. MTT and L-glutamine were
obtained from USB Corporation (Cleveland, OH, USA).
H7, LY294002, SB202190, PD98059, and Pyr-2 were pur-
chased from Calbiochem-Novabiochem (La Jolla, CA, USA).
Racemic mixture of BEL and anti-mouse PGE2 was obtained
from Cayman Chemical (Ann Arbor, MI, USA). Guinea
pig polyclonal antibody anti-mouse PLIN2 and FITC-
conjugated donkey anti-guinea pig antibody were obtained
from Research Diagnostics Inc. (Flanders, NJ, USA). Sec-
ondary antibodies anti-mouse and anti-guinea pig conju-
gated to horseradish peroxidase and nitrocellulose mem-
brane were obtained from GEHealthcare (Buckinghamshire,
UK). Gentamicin was purchased from Schering-Plough, NJ,
USA). DMSO and BSA were obtained from Amresco (Solon,
OH, USA). Mouse monoclonal antibody anti-𝛽𝛽-actin, Nile
Red, RPMI-1640, thiocarbohydrazide, OsO4, and EDAC
were purchased from Sigma Aldrich Co. (St. Louis, MO,
USA). PFAwas purchased fromElectronMicroscopy Science
(USA). Alexa Fluor 488 Goat Anti-mouse IgG was purchased
from Life Technologies (Grand Island, NY, USA). DAPI
and �uoromount G were purchased from Molecular Probes
(Eugene, OR, USA). Donkey serum was obtained from
Jackson ImmunoResearch Laboratories (PA, USA). Triton-
X was obtained from Union Carbide Corporation (Danbury,
USA). GA, thioglycolate, and all salts used were obtained
fromMerck (Darmstadt, Germany).
2.2. Animals. Male Swiss mice (18–20 g) were obtained from
Butantan Institute (São Paulo, Brazil). Animals were housed
in a temperature-controlled room (22–24∘C) with a 12 h
light-dark cycle and fresh water and food ad libitum until
used.is study was approved by the Butantan Institute Ani-
mal Experimentation Ethics Committee (reference number
760/10) in accordance with the procedures laid down by the
Universities Federation for Animal Welfare.
2.3. Phospholipase A2. e Lys49PLA2 homologue (MT-II)
was isolated from Bothrops asper venom by ion-exchange
chromatography on CM-Sephadex C-25 as described [23],
followed by RP-HPLC on a C8 semipreparative column
(10 × 250mm; Vydac) eluted at 2.0mL/min with a 0–70%
acetonitrile gradient containing 0.1% tri�uoroacetic acid,
during 30min, on an Agilent 1200 instrument monitored
at 215 nm. Homogeneity was assessed by analytical reverse-
phase HPLC on a C4 column using a gradient of 0–60%
acetonitrile in 0.1% tri�uoroacetic acid (v/v). e absence
of endotoxin contamination in the MT-II preparation was
demonstrated by the quantitative Limulus amebocyte lysate
(LAL) test [24], which revealed undetectable levels of endo-
toxin (<0.125 EU/mL).
2.4. Synthetic Peptides. e following synthetic peptides
were synthesized and used for biological assays: (a) pep-
tide 115–129 (KKYRYYLKPLCKK) corresponding to the
original sequence 115–129 of MT-II from B. asper snake
venom; (b) peptide p115-W3 (KKWRWWLKPLCKK) cor-
responding to the triple tyrosine-to-tryptophan substitution
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of p115-129; (c) peptide pEM-2 (KKWRWWLKALAKK),
in which the proline and cysteine residues of p115-W3
were each replaced by an alanine residue; (d) peptide 60–71
(KKDRYSYSWKDK) corresponding to a central region
sequence of MT-II; (e) peptide p-Scr (FKFKYKKACKKYK)
corresponding to a scrambled peptide version of the sequence
115–129 of ACL myotoxin, a Lys49 PLA2 homologue from
the venom of the snake Agkistrodon contortrix laticinctus.
Synthetic peptides were prepared in automated bench-
top simultaneous multiple solid-phase synthesizer (PSSM
8 system from Shimadzu Co.) using solid-phase peptides
synthesis by the Fmoc procedure [25�. Brie�y, sequential
couplings of protected amino acids were performed
with HOBt, TBTU and NMM on Fmoc-Lys(Boc)-Wang
resin (Merck KGaA, Germany). Fmoc group cleavage
was performed with 30% piperidine (v/v) in DMF. e
resin-bound peptides were cleaved/deprotected with
TFA/thioanisole/EDT/phenol/water (82.5 : 5: 2.5 : 5 v/v/v/v)
at room temperature for 4 h. Aer �ltration, the �ltrate
was concentrated under argon stream and precipitated with
diethyl ether. All crude peptides were puri�ed by reversed-
phase chromatography (Shim-pack Prep-ODS, Shimadzu
Co.) semipreparative HPLC, and the purity and identity of
the peptide were con�rmed by mass spectrometry and by
analytical HPLC.
2.5. Harvesting of Macrophages. Peritoneal macrophages
were harvested 4 days aer i.p. injection of 1mL of 3%
thioglycolate. Animals were killed under CO2 atmosphere
and cells were harvested by washing peritoneal cavities
with 3mL of PBS, pH 7.2, containing 10 IU/mL heparin.
Aliquots of the washes were used for total cell counts in a
Neubauer chamber aer dilution (1 : 20, v/v) in Turk solution
(0.2% crystal violet dye in 30% acetic acid). Diﬀerential cell
counts were performed on smears stained with Hema3. More
than 95% of the cell population consisted of macrophages,
as determined by conventional morphological criteria. e
remainingwash volumeswere centrifuged at 500×g for 6min
(4∘C) and the cell pellets were used for subsequent studies
aer suitable dilutions.
2.6. Cytotoxicity Assay. Cytotoxicity of MT-II towards
elicited macrophages was evaluated using the MTT assay.
In brief, 2 × 105 macrophages/well in RPMI-1640 medium
supplemented with 40 𝜇𝜇g/mL gentamicin sulfate and 2mM
L-glutamine were plated in 96-well plates and incubated with
100 𝜇𝜇L of selected concentrations of MT-II (0.4–0.8 𝜇𝜇M)
diluted in medium or with the same volume of medium
alone (control) for 1, 6, 12, and 24 h at 37∘C in a humidi�ed
atmosphere (5% CO2). MTT (5mg/mL) was dissolved in
PBS and �ltered for sterilization and removal of a small
amount of insoluble residue present in some batches of
MTT. Stock MTT solution (10% in culture medium) was
added to all wells in each assay, and plates were incubated at
37∘C for 3 h. One hundred 𝜇𝜇L of DMSO were added to all
wells and mixed thoroughly at room temperature for 30min.
Absorbances at 540 nm were then recorded in a microtiter
plate reader. Results were expressed as percentage of viable
cells, considering control cells incubated with medium alone
as 100% viable.
2.7. Stimulation and Treatment of Macrophages. Macro-
phages were plated on glass coverslips in 24-well plates at a
density of 2 × 105 cells/coverslip and allowed to attach for
30min at 37∘C under a 5% CO2 atmosphere. Non-adherent
cells were removed by washing with PBS. Cell monolayers
were cultured for 1 h in RPMI-1640 supplemented with
40 𝜇𝜇g/mL gentamicin sulfate and 2mM L-glutamine at 37∘C
and 5% CO2 and were then challenged with selected con-
centrations of MT-II (0.2–1.2𝜇𝜇M) or synthetic peptides
(250 𝜇𝜇g/mL) or medium (control). Where appropriate, the
following inhibitors were used: 1𝜇𝜇M SB202190, inhibitor of
p38MAPK; 1 𝜇𝜇M LY294002, inhibitor of PI3K; 6 𝜇𝜇M H7-
Dihydro, inhibitor of PKC; 25 𝜇𝜇M PD98059, inhibitor of
ERK1/2; 1 𝜇𝜇M Pyr-2 (Pyrrolidine-2), inhibitor of cPLA2 and
2 𝜇𝜇M BEL (bromoenol lactone) an inhibitor of iPLA2. All
stock solutions were prepared in DMSO and stored at −20∘C.
Aliquots were diluted in RPMI-1640 to the required concen-
tration immediately before use. e �nal DMSO concentra-
tion was always lower than 1% and had no eﬀect on lipid
body numbers. All pharmacological inhibitors were added
between 30 and 60min before stimulation of macrophages
with MT-II or medium (control). Cells treated with the
inhibitors were analyzed for viability by the tetrazolium-
based (MTT) colorimetric assay. No signi�cant changes in
cell viability were registered with any of the above agents or
vehicle at the concentrations used (data not shown).
2.�. �ipid �ody Staining and �uanti�cation. Analysis of lipid
body numbers was performed in osmium-stained cells. In
brief, macrophages (2 × 105 cells) adhered to glass cov-
erslips were �xed in 4% PFA in 0.1M phosphate buﬀer,
pH 7.2, for 15min, and stained with OsO4. e coverslips
were then rinsed in 0.1M phosphate buﬀer, stained in 1%
OsO4 (30min), rinsed in deionized H2O, immersed in 1.0%
thiocarbohydrazide (5min), rinsed again in 0.1M phosphate
buﬀer, restained with 1% OsO4 (3min), rinsed with H2O,
and then dried and mounted. e morphology of the �xed
cells was observed and round osmiophilic structures were
identi�ed as lipid droplets, which were then counted under
phase-contrast microscopy using the 100x objective lens in
50 consecutively scanned leukocytes in each coverslip. For
assays with �uorescent-labeled lipid droplets, macrophages
(2 × 105 cells) adhered to glass coverslips were incubated
with Nile Red staining solution freshly prepared in 0.1M
phosphate buﬀer (10 𝜇𝜇g/mL) for 20min at room temperature
and washed with phosphate buﬀer. Aer several washes the
coverslips were mounted with �uoromount G and examined
under a �uorescence microscope equipped with the appro-
priate �lter (�eiss LSM 510 Meta).
2.9. Electron Microscopy. A standardized protocol for elec-
tronmicroscopy procedure was developed for ultrastructural
analysis of lipid droplets. Macrophages (5 × 106 cells) incu-
bated with either MT-II (0.8 𝜇𝜇M) or medium alone for 1 h
were �xed in a diluted mixture of freshly prepared aldehydes
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(4% PFA/1% GA in 0.1M phosphate buﬀer) containing 3.5%
sucrose for 2 h at room temperature and then washed three
times in 0.1M phosphate buﬀer. Cells were centrifuged at
129×g, and cell pelletswere post�xedwithOsO4 (1% in phos-
phate buﬀer at room temperature) followed by three washes
with saline solution. Uranyl acetate in aqueous solution was
then added for 2 h at room temperature before dehydration
in a graded series of ethanol (70, 95 and 100% twice for
10min each). For embedding, aliquots of propylene oxide
were added twice for 10 minutes, followed by Spurr resin
diluted in propylene oxide (1 : 1) and undiluted Spurr resin
for 12 h. Polymerization was carried out for 48 h at 70∘C.
Samples were then incubated with 4% uranyl acetate and lead
citrate for contrast. in sections were examined with LEO
906E and Zeiss EM109 transmission electron microscopes.
2.10. Immunodetection of PLIN2 and PGE2. Detection of
PLIN2 in MT-II-stimulated macrophages was performed
by PLIN2 immunostaining. In brief, macrophages attached
to coverslips and stimulated for 3 h with MT-II (0.8 𝜇𝜇M)
were �xed in 2% paraformaldehyde (PFA). e cells were
permeabilized with 0.2% Triton-X 100 in 0.1M phosphate
buﬀer and blocked with 0.5% normal donkey serum in 0.1M
phosphate buﬀer for 90min. Aer PBS washes, macrophages
were incubated for 1 h with guinea pig polyclonal anti-mouse
PLIN2 (1 : 2000) diluted in 0.1M phosphate buﬀer with 0.2%
Triton-X 100. Aer three washes with PBS (10min each), the
preparations were incubated for 1 h with secondary FITC-
conjugated donkey anti-guinea pig antibody (1 : 500) in the
dark for 1 h. Aer the washes, the slides were mounted
with �uoromount G and examined under confocal laser
scanning microscope (Zeiss LSM 510 Meta). For analysis of
PGE2 immunostaining, the cell were �xed and permeabilized
in 1% N-ethyl-N�-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDAC) in HBSS−/−. e macrophages were
blocked with 0.5% normal donkey serum in 0.1M phosphate
buﬀer for 60min. Next, the macrophages were washed with
HBSS−/− and incubated for 1 hwith anti-PGE2 (1 : 100). Aer
further washes, cells were incubated with biotinylated rabbit
anti-mouse IgG secondary Ab (1 : 250) and Nile red solution
(1 : 250) in the dark for 1 h. e cover slips were then washed
three times and mounted with �uoromount G containing
DAPI (Vector Laboratories, Burlingame, CA) and examined
under confocal laser scanning microscope (Zeiss LSM 510
Meta).
2.11. Western Blotting of PLIN2. Aliquots of MT-II-stim-
ulated and -nonstimulated cells (2 × 106 cells) were lysed
with 100 𝜇𝜇L of sample buﬀer (0.5M Tris-HCl, pH 6.8,
20% SDS, 1% glycerol, 1M 𝛽𝛽-mercaptoethanol, and 0.1%
bromophenol blue) and boiled for 10min. Samples were
resolved by SDS polyacrylamide gel electrophoresis (SDS-
PAGE) on 10% bis-acrylamide gels overlaid with a 5%
stacking gel. Proteins were then transferred to nitrocellulose
membrane (GE Healthcare, Buckinghamshire, UK) using
a Mini Trans-Blot (Bio-Rad Laboratories, Richmond, CA,
USA). e membranes were blocked for 1 h with 5% nonfat
dry milk in TTBS (20mM Tris, 100mM NaCl and 0.5%
Tween 20) and incubated with primary antibodies against
PLIN2 (1 : 2000 dilution) and 𝛽𝛽-actin (1 : 3000) for 1 h.
ey were then washed and incubated with the appropriate
secondary antibody conjugated to horseradish peroxidase.
Detection was by the enhanced chemiluminescence (ECL)
method according to the manufacturer’s instructions (GE
Healthcare, Buckinghamshire, UK). Band densities were
quanti�ed with a GS 800 Densitometer (Bio-Rad Laborato-
ries, Richmond, CA) using the image analysis soware from
Molecular Analyst (Bio-Rad Laboratories, Richmond, CA,
USA).
2.12. Statistical Analysis. Data are expressed as the mean ±
standard error of mean (SEM) of at least three independent
experiments. Multiple comparisons among groups were per-
formed by one-way analysis of variance (ANOVA) followed
byTukey’s test. Values of probability lower than 5% (𝑃𝑃 𝑃 0𝑃0𝑃)
were considered signi�cant.
3. Results
3.1. Eﬀect of MT-II on Macrophage Viability. Initially, the
eﬀect of MT-II on isolated-elicited macrophage viability was
assessed by the tetrazolium-based (MTT) colorimetric assay.
To this purpose the eﬀect of 24 h incubation with two distinct
concentrations of MT-II (0.8 and 1.6𝜇𝜇M) were evaluated. As
shown in Figure 1, incubation of macrophages with MT-II at
a concentration of 0.8 𝜇𝜇Mdid not aﬀectmacrophage viability.
At a concentration of 1.6 𝜇𝜇M, the sPLA2 homologue partially
decreased (𝑃𝑃 𝑃 0𝑃0𝑃) macrophage viability.
3.2. MT-II Induces LD Formation in Macrophages. To deter-
mine whether stimulation of peritoneal macrophages with
MT-II would lead to LDs formation, these cells were incu-
bated with selected concentrations of MT-II (0.2–1.6 𝜇𝜇M)
for 1 h. As demonstrated in Figure 2(a), incubation of
macrophages with MT-II at concentrations from 0.8 to
1.6 𝜇𝜇M, but not from 0.2 and 0.4 𝜇𝜇M, for 1 h induced a
signi�cant increase (𝑃𝑃 𝑃 0𝑃0𝑃) in the number of LDs in com-
parison with control cells incubated with culture medium
alone. Maximal LD numbers were observed at 1.6 𝜇𝜇M MT-
II. To determine the time-course of LD formation induced
by MT-II, a submaximal concentration of this Lys49PLA2
was used (0.8 𝜇𝜇M), and the number of LDs aer 1–24 h of
incubation was determined. As shown in Figure 2(b), MT-II
caused a signi�cant increase (𝑃𝑃 𝑃 0𝑃0𝑃) in the numbers of
LDs aer 1–24 h incubation compared with control cells.e
highest number of LDs was detected aer 24 h incubation. As
illustrated in Figure 2(c), control macrophages stained with
OsO4 showed very few osmiophilic inclusions in the cyto-
plasm. In contrast, MT-II-stimulated macrophages exhibited
a cytoplasm packed with the osmiophilic organelles, which
can be seen as dark punctate structures in Figures 2(d), 2(e),
and 2(f).
3.3. Ultrastructural Analysis of LDs Induced by MT-II. To
further investigate the stimulatory eﬀect of MT-II leading
to LDs formation in macrophages, ultrastructural analysis
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F 1: Eﬀect of MT-II on cell viability. e cells were incubated
with MT-II (0.8 and 1.6 𝜇𝜇M) or RPMI (control) for 24 h, and cyto-
toxicity was assessed by the tetrazolium-based (MTT) colorimetric
assay. Values represent the mean ± SEM from four animals. ∗𝑃𝑃 𝑃
0.05 compared with control (RPMI).
of LDs was performed using a standardized procedure for
TEM. As seen in Figure 3(a) control macrophages showed
small, non-membrane-bound, light cytoplasmic LDs. Aer
1 h incubation, MT-II-stimulated macrophages showed light
cytoplasmatic LDs that were present in markedly greater
numbers than in the control cells butmorphologically similar
to LDs in these cells (Figure 3(b)). Also, an enlarged ER
was observed in MT-II-stimulated cells in incubation period
tested as showed in Figure 3(c).
3.4. Eﬀects of Peptides Corresponding to Selected Regions
of MT-II Molecule on LD Formation. e eﬀects of syn-
thetic peptides derived from distinct regions of MT-II pro-
tein on LDs formation were investigated in macrophages.
Experiments were carried out with macrophages stimulated
with peptides corresponding to distinct regions of MT-II
molecule for 3 h and then treated as necessary for lipid
�xation and stained with OsO4. Figure 4(a) demonstrates
that incubation of macrophages with the C-terminal peptide
p115-129 induced a signi�cant increase (𝑃𝑃 𝑃 0.05) in the
number of LDs aer 3 h of incubation in comparison with
nonstimulated control cells. e eﬀect induced by this C-
terminal peptide did not diﬀer from that observed in cells
stimulated with MT-II native protein for 3 h, which caused
a signi�cant increase in the number of LDs in comparison
with control cells. On the other hand, neither a scrambled
version of the residue sequence used as a control, p-Scr, nor
the peptide comprising amino acid residues 60–71 of central
region of MT-II modi�ed the basal numbers of LDs aer
3 h of incubation as compared with RPMI-treated control
cells. As a positive control macrophages were incubated
with MT-II native protein for 3 h. In this case, a signi�cant
increase in LD number was detected in comparison with
RPMI-treated control cells. All peptides tested were used
in a concentration (250 𝜇𝜇g/mL) previously demonstrated in
literature as eﬀective to induce biologic eﬀects (32), but
without toxic eﬀect on the viability of macrophages aer 3 h
of exposure. Figure 4(b) demonstrates that incubation of cells
with peptides p115–129, pScr, and p60–71 at a concentration
of 250 𝜇𝜇g/mL did not aﬀect macrophages viability, whereas
incubation of cells with peptides pEM2 (150 𝜇𝜇g/mL) and
p115-W3 (150 𝜇𝜇g/mL) signi�cantly (𝑃𝑃 𝑃 0.05) reduced the
viability of macrophages making these peptides unsuitable
for the present study. Although MT-II is recognized as a
sPLA2 devoid of catalytic activity, we investigated whether
a possible residual enzyme activity of MT-II would lead
to formation of LDs in macrophages. As shown in Figure
4(c) incubation of macrophages with MT-II (0.8𝜇𝜇M) for
1 h in the presence of a Ca2+-containing medium induced
a signi�cant increase (𝑃𝑃 𝑃 0.05) in the number of LDs.
is MT-II-induced eﬀect was not modi�ed in the presence
of Ca2+-free, EGTA- and Sr+2 -containing medium, with a
signi�cant increase of LD numbers observed in comparison
with respective control group.
3.5. LD Formation Triggered by MT-II Is Dependent on
Distinct Signaling Pathways. To assess the role of kinases in
the described actions of MT-II, we determined the eﬀects
of the speci�c inhibitors of p38, PI3K, PKC, and ERK1/2
(SB202190, LY294002, H7-Dihydro, and PD98059, resp.) on
MT-II-induced LDs in macrophages. As seen in Figure 5(a),
the PI3K and PKC inhibitors abolished the LDs formation
in MT-II-stimulated macrophages compared with vehicle-
treated macrophages stimulated with MT-II. e ERK1/2
inhibitor, in turn, caused 49% reduction in the number of
LDs in MT-II-stimulated macrophages when compared with
vehicle-treated macrophages stimulated with MT-II (Figure
5(b)). In contrast, the preincubation of macrophages with
p38MAPK inhibitor did not change the number of LDs
induced by MT-II, in comparison to cells stimulated with
MT-II only (Figure 5(b)).
3.6. MT-II Upregulates PLIN2 Protein Expression in MT-II-
Stimulated Macrophages. PLIN2 expression can be induced
by a variety of in�ammatory cells and has been associated
with increased numbers of LDs [26, 27]. erefore, we
investigated whether MT-II induces expression of this LD
structural protein. Levels of PLIN2 protein expression were
analyzed by western blotting in cells incubated and not
incubated with MT-II for selected time periods.is analysis
revealed increased expression of PLIN2 protein in cells
stimulated with MT-II as early as 3 h of incubation, which
was sustained up to 12 h. PLIN2 was minimally expressed or
absent in control nonstimulated macrophages (Figures 6(a)
and 6(b)).
3.7. PLIN2 Colocalizes to LDs in MT-II-Stimulated Macro-
phages. To better understand the stimulatory eﬀect of MT-
II on macrophages that leads to LD formation, cells exposed
to MT-II were immunostained with speci�c antibodies that
recognize PLIN2 or neutral lipids from the LD core. As
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F 2: MT-II induces formation of LDs in peritoneal macrophages in culture. (a) Eﬀect of selected concentrations of MT-II on formation
of LDs in macrophages which were incubated with various concentrations of MT-II or with RPMI (Control) for 1 h. (b) Time-course of MT-
II-induced LD formation. Macrophages were incubated with MT-II (0.8 𝜇𝜇M) or RPMI (Control) for 1, 3, 6, 12, or 24 h. LDs were �uanti�ed
using light microscopy aer osmium staining. LDs aer osmium staining observed in control (c) or in cells stimulated with MT-II (0.8 𝜇𝜇M)
for 1 h (d), 12 h (e), or 24 h (f). Each bar represents themean ± S.E.M. of the number of LDs/cell in 50 counted cells. Values represent means ±
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+𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 compared with cells stimulated by MT-II (0.8 𝜇𝜇M) for 1, 3, 6 and 12 h.
illustrated in Figure 7 macrophages stimulated with MT-II
(0.8𝜇𝜇M) for 3 h e�hibited strong �uorescent staining (green)
for PLIN2, with a punctate cytoplasmic pattern, which
was absent in the nonstimulated control cells. Fluorescent
Nile Red-labeled LDs were also visualized 3 h aer MT-II-
induced stimulation and were virtually absent in nonstim-
ulated control macrophages. Aer stimulation with MT-II,
cytoplasmic-stained PLIN2 matched perfectly with Nile
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F 3: MT-II-induced LDs are morphologically distinct cytoplasmic sites. (a) Control macrophages with typical morphology. (b) and (c)
Macrophages incubated with MT-II (0.8 𝜇𝜇M) for 1 h showing light and large cytoplasmic lipid droplets (LDs). Also, an enlarged ER can be
observed in MT-II-stimulated cells. N: nucleus.
Red-marked, neutral lipid inclusions. As expected, no signif-
icant staining was detected in control macrophages.
3.8. Involvement of Intracellular PLA2s in MT-II-Induced LD
Formation inMacrophages. Since a cross-talk between sPLA2
and intracellular PLA2s for production of prostaglandins has
been described,we examined the eﬀects of selective inhibitors
of cPLA2(Pyr-2) or iPLA2 (BEL) onMT-II induced formation
of LDs. As shown in Figure 8, treatment of macrophages with
BEL, but not with Pyr-2 compound caused 51% reduction
in the number of LDs in MT-II-stimulated macrophages
compared with vehicle-treated cells stimulated with MT-II.
ese results indicate that iPLA2, but not cPLA2 is involved
in MT-II-induced LD biogenesis.
3.9. PGE2 Colocalizes within LD Induced byMT-II-Stimulated
Macrophages. �nder in�ammatory conditions, lipid media-
tors are mainly produced within LBs, which compartmen-
talize both substrate and the enzymatic machinery required
for eicosanoid production [28]. Considering that PGE2 is the
major prostaglandin produced in macrophages, we evaluated
the subcellular localization of PGE2 withinMT-II-stimulated
macrophages. As illustrated in Figure 9 immuno�uorescence
microscopy revealed that macrophages stimulated with MT-
II (0.8 𝜇𝜇M) for 3 h exhibited strong �uorescent staining
(green) for PGE2, with a punctate cytoplasmic pattern, which
was diﬀuse in the nonstimulated control cells. Fluorescent
Nile Red-labeled LBs were also visualized 3 h aer MT-
II-induced stimulation and were virtually absent in non-
stimulated control macrophages. Overlapping images show
that aer stimulation with MT-II, cytoplasmic-stained PGE2
matched perfectly with Nile Red-marked, neutral lipid inclu-
sions. As expected, no signi�cant staining was detected in
control macrophages.
4. Discussion
Besides myotoxic activity, MT-II, a Lys49PLA2 homologue,
has been shown to activate some cellular processes in
macrophages at noncytotoxic concentrations [4, 5], and these
eﬀects may contribute to the overall tissue alterations caused
by this toxin. �pon in�ammatory conditions, macrophages
show increased numbers of cytoplasmic LDs, which have
been implicated as key organelles involved in immunity and
in�ammation.
In this study, we showed that MT-II, a catalytically inac-
tive PLA2 homologue, was able to directly induce an increase
in the numbers of LDs in isolated murine macrophages. is
phenomenon was time dependent and had a very fast onset
and persisted up to 24 h aer stimulation. Within 1 h of MT-
II stimulus the presence of weakly osmiophilic LDs, in close
association with organelles such as endoplasmic reticulum,
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F 4: Eﬀects of peptides corresponding to selected regions of MT-II molecule on LD formation. (a) Peritoneal macrophages were
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or PEM2 (150 𝜇𝜇g/mL) or p115–W3 (150 𝜇𝜇g/mL) or RPMI (control) for 3 h, aer which cytotoxicity was assessed by the tetrazolium-based
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control cells.
were evidenced by the ultrastructural analysis. According
to the current model of LD biogenesis, these organelles
arise from endoplasmic reticulum, where the enzymes that
synthesize lipids reside [15, 29]. erefore, endoplasmic
reticulum may play a role in LDs biogenesis induced by
MT-II.
Because LDs have been associated to regulated in�am-
matory mediator synthesis with roles in in�ammatory and
infectious conditions, and macrophages are central elements
in the innate immune response it is plausible to consider
that biogenesis of LDs induced by MT-II demonstrated
herein represents an important mechanism by which this
PLA2 homologue displays an in�ammatory response and
leads to production and release of in�ammatory mediators.
Moreover, considering that basic PLA2s comprise around
30% of B. asper venom [30], the fact that MT-II elicited a
�ey in�ammatory event inmacrophages clearly indicates that
this sPLA2 homologue contributes to the local in�ammatory
response triggered by the whole venom.
In addition, our data demonstrated that the absence
of Ca2+ and presence of Sr2+ in culture medium did not
alter LDs formation induced by MT-II, con�rming that
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F 5: Signaling pathways involved in MT-II-induced LD for-
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stimulated cells.
the catalytic activity is not an essential requirement to
enhancement of LDs biogenesis by MT-II. A number of
experimental evidences suggested that a stretch of residues,
located at the C-terminus of the MT-II protein molecule,
and involving cationic and hydrophobic amino acids are
responsible for myotoxic and cytotoxic eﬀects of this [9, 31,
32] and other Lys-49sPLA2 homologues [31, 33]. Based on
these and other studies, a model of Lys49PLA2s-membrane
interaction was proposed by Lomonte et al. [9] in which
the action of Lys49PLA2s is based on the interaction of
the C-terminal positive residues with membrane anionic
phospholipids. So far, in the present study we found that
the synthetic peptides 115–129 corresponding to MT-II C-
terminus peptide induced LD formation in macrophages
similarly to the parent protein. is �nding indicates for the
�rst time the speci�c region of MT-II molecule responsible
for activation of macrophages, and gives support to the
notion that the eﬀects of MT-II in leukocytes are not related
to the PLA2 enzymatic activity. e membrane target(s) and
the mechanisms by which this C-terminal peptide triggers
macrophages activation to form LDs were not addressed in
this study, although perturbation of the membrane phospho-
lipid bilayer is likely to be involved.
Perilipin 2 is a protein ubiquitously expressed in a
number of cell types, including macrophages, as a major
component of intracellular LDs [34, 35]. It has fatty acid-
binding properties, contributes to cytoplasmic traﬃcking of
newly synthesized lipids, and plays an important role in
assembly of LDs as well as in foam cell formation [35–37].
PLIN2 expression can be induced by a variety of in�amma-
tory stimuli and has been associated with increased numbers
of LD [26, 27]. Consistent with its properties, PLIN2 has been
considered as a marker of LDs assembly and lipid loading in
in�ammatory cells, such as macrophages. Accordingly, our
results showed that PLIN2 protein expression is upregulated
byMT-II, given support to data demonstrating LD formation
upon stimulus by this PLA2 homologue. Furthermore, PLIN2
clustering co-localized to LDs was seen indicating that MT-II
is also able to recruit this protein from its constitutive pools
into LDs, and suggesting a role for PLIN2 as a nucleation site
for the assembly of lipids to form new LDs under the stimulus
of this Lys49PLA2.
LD biogenesis in leukocytes is a highly regulated process.
Studies of the intracellular signaling pathways committed
to this process in leukocytes have revealed that distinct
pathways can trigger LD biogenesis in a stimulus-dependent
manner [38]. To better understand the stimulatory eﬀects
of MT-II on LD formation, we herein used pharmacological
approaches to identify the critical downstream signaling
proteins involved in LD formation induced by this PLA2
homologue and focused on major downstream signaling
molecules that have previously been shown to participate
in LD biogenesis which follows in�ammatory stimuli, such
as PKC [39, 40], PI3K [16, 26] and MAPKs (p38MAPK and
ERK1/2) [16, 41]. As a marked LD formation was observed
aer 3 h of incubation, the eﬀects of pharmacological com-
pounds were evaluated at this time interval. We found
that MT-II-induced LD formation is regulated by speci�c
signaling pathways and that PKC, PI3K, ERK1/2, but not
p38MAPK are involved in the formation of LD induced by this
PLA2 homologue.
�ur �nding thatmacrophage activation byMT-II to form
LDs is largely dependent on the PKC agrees with previous
reports that PKC activation is implicated in LD formation
induced by cys-fatty acid and PAF in leukocytes [39, 42].
Considering that activation of PKC has been associated with
increased expression of PLIN2 inmacrophages [43], it is pos-
sible to suggest that in the present experimental conditions,
PKC signaling pathway is important to MT-II-induced up-
regulation of PLIN2, and thus to the increased formation of
LDs. Moreover, our observation that LDs formation induced
by MT-II requires activation of the PI3K pathway is in line
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F 7: PLIN2 and LD colocalize in macrophages stimulated by MT-II. Macrophages incubated with RPMI (control) or MT-II (0.8 𝜇𝜇M)
for 3 h were labeled for LDs (�uorescent Nile Red) and for PLIN2 (FITC-con�ugated immunocomplex). Merged image shows colocalization
of PLIN2 to LDs. Cell nuclei are observed by DIC. e pictures are representative of three independent experiments.
with reports of participation of this signaling protein in
processes related to lipid accumulation [26, 44, 45] and in
the regulation of PLIN2 which has been largely associated to
lipid accumulation into LDs, and to atherosclerosis [26, 45].
Furthermore, our results implicating ERK1/2 signaling in the
MT-II eﬀect that leads to LD formation in macrophages are
consistent with previous studies demonstrating the involve-
ment of ERK1/2 in LDs biogenesis induced by cytokines
and saturated fatty acids in macrophages [16, 46]. Moreover,
evidences of the involvement of ERK1/2 in regulation of
PLIN2 expression and the growth of LDs [41] give support to
our �ndings of increased protein expression of PLIN2 seen
under MT-II stimulus, and is in line with the involvement of
ERK1/2 in biogenesis of LDs induced by this PLA2 homo-
logue. Conversely, the speci�c inhibitor of p38MAPK failed
to inhibit MT-II-induced LD formation, implying that this
MAPK element does not contribute to this MT-II-induced
eﬀect. Taken together, the above results evidenced that MT-
II-induced LD formation is a regulated process associated
to activation of selected downstream signaling pathways in
BioMed Research International 11
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macrophages. Of note, despite the lack of enzyme activity,
MT-II triggers signaling pathways almost similar to those that
signal increased formation of LDs induced by the catalytically
active sPLA2 MT-III in macrophages [22], thus providing an
additional evidence of functional similarities between these
two venom sPLA2variants.
It has beendemonstrated that LDs are involved in produc-
tion of in�ammatory mediators [28] and to act as platforms
for enhanced PGE2 synthesis during infection conditions
[47, 48]. Moreover, a number of enzymes and signaling
proteins were shown to be associated with LDs, including
the prostaglandin-forming enzymes named cyclooxygenases
[47]. Our �ndings that MT-II caused an increase of PGE2
intracellular pools, which colocalized to LDs in macrophages
represent the �rst evidence that a sPLA2 homologue is able
to induce synthesis and compartmentalization of a lipid
mediator in LDs.ese �ndings suggest that macrophage LD
constitutes a relevant site for the synthesis and accumulation
of eicosanoids underMT-II stimuli andmay represent a rapid
and alternative mechanism for PGE2 production by which
macrophages react to activation by this sPLA2 homologue.
Moreover, given the importance of PGE2 in several in�am-
matory settings, due to its hyperalgesic and edematogenic
properties [49, 50], it is reasonable to suggest that LD-
derived PGE2 may have implications for the in�ammatory
eﬀects of MT-II. is hypothesis is in line with the view
that LDs are dynamic organelles integrating lipidmetabolism,
in�ammatory mediator production, membrane tra�cking,
and intracellular signaling [27, 47, 51].
A number of studies have demonstrated that secreted
PLA2s crosstalk with the intracellular PLA2s (cPLA2 and
iPLA2) to produce arachidonic acid- (AA-) derived in�am-
matory mediators, such as prostaglandins, in several patho-
physiological conditions [52, 53]. cPLA2 is recognized as
a key regulator of stimulus-coupled cellular AA release
[6, 54]. e iPLA2 in turn has no substrate speci�city for
the fatty acid residue at sn-2 position, playing a minor role
in eicosanoid synthesis. is intracellular enzyme, however,
has a role in membrane phospholipid remodeling through
deacylation/reacylation reactions [55]. In this context, cPLA2
and iPLA2 were demonstrated to be involved in LD bio-
genesis induced by stress in CHO-K1 cells [56] and by the
Asp49PLA2 MT-III in macrophages [22]. Taking the above
information into account we investigated the participation
of both intracellular PLA2 isoforms in MT-II-induced LD
formation. We found that treatment of macrophages with,
compound Pyr-2, a speci�c inhibitor of cPLA2 failed to
inhibit MT-II-induced eﬀect, indicating that cPLA2 is not
required for LD formation under MT-II stimulus. is
�nding is in accordance with our observation that p38MAPK
is not involved in LD formation induced by MT-II, as
upstream p38MAPK is critical for phosphorylation and acti-
vation of cPLA2 [57]. In contrast, inhibition of iPLA2 by BEL
compound signi�cantly reduced LD formation, thus imply-
ing iPLA2 in the mechanisms involved in MT-II-induced
LD formation. is �nding is supported by recent studies
demonstrating participation of iPLA2s in the metabolism of
fatty acids and triacylglycerol formation, which are involved
in LD formation [56]. We believe that our results are the
�rst demonstration that a sPLA2 devoid of catalytic activity
recruits an intracellular PLA2 (iPLA2) to induce a cellular
event, such as LD formation in macrophages. However, the
cellular steps involved in such a protein crosstalk were not
addressed in the present study and deserve further studies.
5. Conclusions
Taken together, our data show that the venom group IIA
sPLA2 homologue MT-II directly activates murine macro-
phages to form LDs by a mechanism independent on enzy-
matic activity. is eﬀect is related to the C-terminal loop of
the MT-II molecule since a synthetic peptide corresponding
to region 115–129-induced LD formation similarly to MT-
II. Moreover, MT-II-induced LD formation is related to
increased expression and recruitment of PLIN2 from its con-
stitutive pools and regulated by distinct signaling pathways
that include PKC, PI3K, ERK1/2, and iPLA2. In addition,
MT-II induced synthesis and compartmentalization of PGE2
within LDs. erefore, LDs may represent and important
platform for the synthesis and accumulation of lipid media-
tors underMT-II stimulus that takes place in themechanisms
whereby this Lys49PLA2 triggers in�ammation.
Finally, considering that catalytically inactive PLA2s have
been also described in mammalian tissues under normal
and pathological conditions [58, 59], this study may shed
light on the possible activities of similar proteins on a
more general scope, providing insights into the possible
roles of human catalytically inactive PLA2 homologues in
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F 9: Cytoplasmic lipid droplets compartmentalize PGE2. Macrophages incubated with RPMI (control) or MT-II (0.8 𝜇𝜇M) for 3 h were
labeled for LBs (�uorescent Nile Red) and for PGE2 (Cayman Chemical). Merged image shows colocalization of PGE2 to LDs. Cell nuclei are
observed by DIC. e pictures are representative of three independent experiments.
in�ammatory conditions as it has been demonstrated for the
snake venom Lys49PLA2.
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